The immune response in multiple sclerosis

S Rodríguez Murúa, MF Farez… - Annual Review of …, 2022 - annualreviews.org
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative
disease that affects the central nervous system (CNS). MS is characterized by immune …

From target discovery to clinical drug development with human genetics

K Trajanoska, C Bhérer, D Taliun, S Zhou, JB Richards… - Nature, 2023 - nature.com
The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

Ankylosing spondylitis: etiology, pathogenesis, and treatments

W Zhu, X He, K Cheng, L Zhang, D Chen, X Wang… - Bone research, 2019 - nature.com
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic
inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic …

Treatment of axial spondyloarthritis: an update

A Danve, A Deodhar - Nature Reviews Rheumatology, 2022 - nature.com
Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the
past two decades. With advances in the discernment of immunopathogenesis of this …

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

D Baeten, M Østergaard, JCC Wei, J Sieper… - Annals of the …, 2018 - ard.bmj.com
Objectives To evaluate the efficacy and safety of risankizumab, a humanised monoclonal
antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing …

Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis

A Deodhar, LS Gensler, J Sieper, M Clark… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …

The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing

SL Gaffen, R Jain, AV Garg, DJ Cua - Nature reviews immunology, 2014 - nature.com
Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major
revision of the TH subset paradigm and substantial progress has been made in deciphering …

Innate and adaptive immunity in inflammatory bowel disease

A Geremia, P Biancheri, P Allan, GR Corazza… - Autoimmunity …, 2014 - Elsevier
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC).
The exact cause of IBD remains unknown. Available evidence suggests that an abnormal …

Five years of GWAS discovery

PM Visscher, MA Brown, MI McCarthy… - The American Journal of …, 2012 - cell.com
The past five years have seen many scientific and biological discoveries made through the
experimental design of genome-wide association studies (GWASs). These studies were …

Effector T helper cell subsets in inflammatory bowel diseases

T Imam, S Park, MH Kaplan, MR Olson - Frontiers in immunology, 2018 - frontiersin.org
The gastrointestinal tract is a site of high immune challenge, as it must maintain a delicate
balance between tolerating luminal contents and generating an immune response toward …